MITF and angiomyolipoma: Moreover, we found that the prevalence of BAP1, FLCN, and MITF p.E318K alterations in this cohort was 6.2% (5 of 81 patients, after excluding benign renal neoplasia, such as oncocytoma and angiomyolipoma; 95% CI 2.3%-14.5%).